As neuroscience research and drug development advance, understanding what is happening in the brain remains a fundamental challenge. Quantitative MRI can provide detailed measures of brain structure and physiology, while PET adds complementary molecular and functional read-outs. Together, these imaging approaches can deepen our understanding of disease biology and help researchers investigate how potential treatments interact with the brain.
At the Clinical Trials on Alzheimer’s Disease (#CTAD2026) meeting this week in Boston, researchers from Karolinska Institutet will share findings from a pilot study using PET, MRI and fluid biomarkers to investigate rapamycin treatment in people with early Alzheimer’s Disease. Martin Schain from Antaros Medical has contributed to the study and is a co-author on the abstract.